OncoMatch/Clinical Trials/NCT06245330
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
Is NCT06245330 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AST-001 for solid tumor.
Treatment: AST-001 — A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Pancreatic Cancer
Biomarker criteria
Required: AKR1C3 strongly positive expression (strongly positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
An adequate renal, liver and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06245330 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require AKR1C3?
Yes, AKR1C3 strongly positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages